LXRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lexicon Pharmaceuticals Inc (LXRX) is not a strong buy at the moment for a beginner investor with a long-term focus. While there are some positive technical indicators and analyst ratings, the company's financial performance is weak, and there are no significant catalysts or trading signals to suggest immediate upside potential. Holding off on investment until more favorable conditions or catalysts emerge is recommended.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 72.102, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 1.846 and 1.926, with support levels at 1.586 and 1.506. However, the stock's candlestick patterns suggest a 30% chance of a -0.87% decline in the next day and a -2.88% decline in the next week.
Analysts have raised price targets recently, with Citi increasing the target to $2.30 and H.C. Wainwright raising it to $6, citing increased probability of success for pilavapadin and potential partnerships.
No recent news or significant hedge fund/insider trading activity. The financial performance in Q4 2025 showed significant declines in revenue (-79.31% YoY), net income (-54.01% YoY), and EPS (-55.56% YoY).
In Q4 2025, revenue dropped to $5.49M (-79.31% YoY), net income dropped to -$15.53M (-54.01% YoY), and EPS dropped to -0.04 (-55.56% YoY). Gross margin also declined slightly to 96.34% (-2.38% YoY).
Analysts maintain a Buy rating with raised price targets: Citi at $2.30 and H.C. Wainwright at $6. H.C. Wainwright noted increased confidence in pilavapadin and potential partnerships.
